新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Auris Medical筹集5000万美元深入研究治疗听力丧失药物

Auris Medical筹集5000万美元深入研究治疗听力丧失药物

来源:生物谷 2013-04-19 21:44

2013年4月19日讯 /生物谷BIOON/ -- 瑞士制药公司Auris公司已经筹集了5000万美元支持公司对内耳疾病治疗药物的研究。目前公司正在研发治疗急性内耳耳鸣的药物AM-101和治疗感觉神经性听力损失的药物AM-111。

近年来,各大制药巨头纷纷将视线转移到耳部疾病药物的研发,如Pfizer,Roche,Novart和Sanofi 等都在该领域投入资金。(生物谷Bioon.com)

详细英文报道:

Swiss biotech Auris Medical has raised $50.6 million in a Series C round of financing to advance its two major therapeutics for the treatment of inner ear disorders.

The company is developing cell-penetrating peptide drugs AM-101, for acute inner ear tinnitus--the ringing effect that follows trauma from noise or surgery--and AM-111 for acute sensorineural hearing loss.

"Having established proof of concept in Phase IIb studies, we are now ready to move forward with our clinical development plans," Thomas Meyer, Auris' founder and managing director said.

The fresh round of financing comes after the company in November 2012 reported positive results from a phase IIb for AM-111 conducted in Germany, Poland and the Czech Republic that involved 210 patients.

Auris also just wrapped up a Phase II clinical trial for AM-101 in the U.S., Belgium, Germany and Poland. According to a February statement on its website, the company will release results of the study this summer.

Leading venture capital firms Sofinnova Ventures of Menlo Park, CA, and Sofinnova Partners of Paris, France, participated in the financing.

Recently, Big Pharma has boosted its interest in developing drugs for hearing conditions--a potential multibillion market. Pfizer ($PFE) is in early-stage development of a treatment that improves the function of hair cells that impact hearing, and Swiss drug giant Roche ($RHHBY) partnered with Versant Ventures in October 2012 to advance research of hearing loss drugs. Novartis ($NVS) and Sanofi ($SNY) have stakes in this area of research, too.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库